Gruntal & Co.

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Retrieved on: 
Lunedì, Aprile 8, 2024
MSD, Employment, Fordham University, Biotechnology, CFO, Patient, Research, Merck, Gruntal & Co., Acquisition, IPO, MBA, Initial, Therapy, HSBC, Gene Mack, Pharmaceutical industry

BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.

Key Points: 
  • BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
  • “We are thrilled to welcome Gene as our new CFO,” commented Gain CEO Matthias Alder.
  • Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023.
  • “I am excited to join Gain Therapeutics during this important stage of corporate growth and scientific progression.

Matrix Executions Continues its Focus on Growth; Embarks on 2023 with Internal Promotions, Expanded Sales Team and SPX Group

Retrieved on: 
Mercoledì, Febbraio 15, 2023
Consulting, Data Management, Technology, Professional Services, Business, Other Technology, Networks, Internet, Fintech, Hardware, Finance, Maker, SPX, Banq, Deutsche Bank, KCG, Capital punishment, GTS, BNP Paribas, Credit Suisse, Bank of America, CBOE, Knowledge, Morgan Stanley, Growth, Bank, Banc of America Securities (1998–2008), Citigroup, Market maker, Security (finance), Matrix, Gruntal & Co.

To support Matrix’s continued growth in 2023, Matrix is excited to welcome two new Senior Sales Executives with decades of experience to its expert team -- Brian Brophy and Robert Frain. Mr. Brophy started his options trading career in 1991 with Société Générale, later trading options at firms that included BNP Paribas, Deutsche Bank, Bank of America, and Credit Suisse. In 2010, Brian Brophy launched RBS’s equity derivative sales in North America.

Key Points: 
  • Matrix Executions congratulates Bryan Radigan in becoming the company’s new Head of Electronic Sales.
  • Since joining the Matrix Executions team in 2018, Bryan Radigan has served as an important ambassador for the company during his tenure as a core member of the Matrix Sales team.
  • It’s an honor to now be able to shape our company strategy and future successes as Matrix’s Head of Electronic Sales.
  • Robert Frain joins Matrix as with deep knowledge of both the U.S. and Canadian electronic options and equity markets with a focus on institutional sales.

DGAP-News: Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Retrieved on: 
Mercoledì, Novembre 3, 2021
MSD, CFO, Biotechnology, IPO, Lazard, Peptide, Catholic University of Leuven (1834–1968), Disease, MBA, HSBC, Patient, Gruntal & Co., Degenerative disease, Catholic higher education, Company, Clinical trial, Acquisition, Cell death, CD4, Gene Mack, Fordham University, Security (finance), Pharmaceutical industry, Vaccine

Lige, Belgium, November 3, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

Key Points: 
  • Lige, Belgium, November 3, 2021 - Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.
  • "We are thrilled to welcome Gene as our new CFO," said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse.
  • Mr. Mack joins Imcyse from OncoC4, a privately held biotechnology company that spun out of MSD's acquisition of OncoImmune.
  • Beyond type 1 diabetes, Imcyse is developing a pipeline of Imotopes(TM) for the treatment of several autoimmune diseases.

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

Retrieved on: 
Mercoledì, Novembre 3, 2021
Child development stages, CFO, Biotechnology, Peptide, IPO, Lazard, Catholic University of Leuven (1834–1968), Disease, MBA, HSBC, Patient, Gruntal & Co., Degenerative disease, Catholic higher education, Company, Clinical trial, Acquisition, Cell death, CD4, GLOBE, Gene Mack, Fordham University, Vaccine

LIGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.

Key Points: 
  • LIGE, Belgium, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the appointment of Gene Mack, MBA, as Chief Financial Officer.
  • We are thrilled to welcome Gene as our new CFO, said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse.
  • Mr. Mack joins Imcyse from OncoC4, a privately held biotechnology company that spun out of MSDs acquisition of OncoImmune.
  • In addition to orchestrating the successful transaction between the two companies, he oversaw OncoC4s financial establishment.

Coya Therapeutics Appoints Gene Mack as Chief Financial Officer

Retrieved on: 
Martedì, Ottobre 12, 2021
Columbia University College of Dental Medicine, HSBC, Columbia University Vagelos College of Physicians and Surgeons, Cryopreservation, Degenerative disease, Therapy, Surgeon, Cerebrovascular disease, Gruntal & Co., Negotiation, Weill Cornell Medicine, Exosome, Merck, Wall Street, GLOBE, MBA, Frontotemporal dementia, Growth, CFO, Industry, Aneurysm, ALS, Pectus carinatum, Gene Mack, Coya, Stroke, Lazard Capital Markets, Physician, BS, Acquisition, Disease, Patient, Fordham University, Research, TM, Pharmaceutical industry

HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointment of Gene Mack as Chief Financial Officer effective immediately.

Key Points: 
  • HOUSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc. (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Treg) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced the appointment of Gene Mack as Chief Financial Officer effective immediately.
  • We are pleased to welcome Gene, an esteemed biotech executive, at such an exciting time for Coya, said Howard Berman, Ph.D., Chief Executive Officer of Coya Therapeutics.
  • Gene has deep financial and business development expertise, as well as a strong track record for enhancing operational capabilities to drive growth.
  • Prior to joining Coya Therapeutics in 2021, Mr. Mack was Chief Financial Officer of OncoC4 overseeing the spin-out and negotiation of Merck MSDs acquisition of OncoImmune.

Stockholder Group Mails Proxy Statement and BLUE Proxy Card in Connection with Evercel Inc.’s 2021 Annual Meeting of Stockholders

Retrieved on: 
Lunedì, Settembre 27, 2021
Senior management, Donaldson, Adoption, ALL, Burnham, Internet, BYLAW, Board of directors, Secondary research, Letter, Negotiation, Liquidity, Gruntal & Co., Donaldson, Lufkin & Jenrette, NASDAQ, Share repurchase, Annual general meeting, Annual Meetings of the International Monetary Fund and the World Bank Group, Board, GLOBE, Herzfeld, Investment, Company, Program, THE, BLUE, INTERNET, Telephone, Partner, TODAY, Performance, Director, Holding company, Management, Online gambling, Security (finance), Financial services, Motor vehicle

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- James D. Gerson and Richard A. Krantz (collectively, the “Stockholder Group” or “we”), the collective owners of approximately 12.0% of the outstanding voting stock of the Company, today announced that it has mailed a proxy statement and BLUE proxy card to solicit votes in favor of its three business proposals seeking to amend Evercel’s Bylaws in order to allow stockholders to expand the size of the Board of Directors (the “Board’) and fill the resulting vacancies with its slate of three highly-qualified directors – Daniel Lewis, Richard Lewisohn III and Alan Mitrani (the “Nominees”) – at the Company’s annual meeting of stockholders scheduled to be held virtually at 10:00 a.m. Eastern Time on Thursday, October 7, 2021 (the “Annual Meeting”).

Key Points: 
  • The Stockholder Group notes that the Companys 2021 financial statements are still not available, despite the year ending almost 6 months ago.
  • The Stockholder Group has concerns with the level of compensation paid to the Companys CEO, Daniel Allen, despite the Companys underperformance.
  • The Stockholder Group believes this announcement was a direct reaction to our proxy statement and proposals, and is intended to distract stockholders from the Companys longstanding lack of performance.
  • Please follow the instructions located on your BLUE proxy card and/or BLUE voting instruction form.

BTIG Healthcare Investment Banking Adds Doug Kleinberg to Bolster Corporate Client Coverage

Retrieved on: 
Giovedì, Maggio 20, 2021
Professional services, Health, Finance, General Health, Pharmaceutical, Banking, Biotechnology, Ladenburg Thalmann, Gruntal & Co., Service companies, Companies, Financial services

At BTIG, Mr. Kleinberg will focus on investment banking opportunities for corporate clients across biotech, biopharma and pharma.

Key Points: 
  • At BTIG, Mr. Kleinberg will focus on investment banking opportunities for corporate clients across biotech, biopharma and pharma.
  • Stone, Managing Director and Head of BTIG Healthcare Investment Banking.
  • Earlier in his career, Mr. Kleinberg was a Director of Healthcare Investment Banking at Ladenburg Thalmann and served in several positions including Managing Director within Healthcare Investment Banking at Gruntal.\n\xe2\x80\x9cWe are pleased to welcome Doug to our Healthcare Investment Banking unit,\xe2\x80\x9d commented Matt Clark, Managing Director and Head of BTIG Investment Banking.
  • Aftermarket services include trading, corporate access, as well as proprietary research and strategy products.\n\xe2\x80\x9cWe are very excited to have Doug join BTIG Healthcare Investment Banking.